Welcome to our dedicated page for PETVIVO HOLDINGS news (Ticker: PETV), a resource for investors and traders seeking the latest updates and insights on PETVIVO HOLDINGS stock.
PetVivo Holdings Inc (PETV) is an emerging biomedical device company with a focus on licensing and commercializing innovative medical devices for pets, known as pet therapeutics. The company aims to capitalize on investments in the human biomaterials and medical device industries to bring therapeutics to pets efficiently. As part of its strategy, PetVivo in-licenses proprietary products from human medical device companies for pet use. Its wholly-owned subsidiaries include PetVivo, Inc., Gel-Del Technologies, Inc., and CosmetaLife Corporation.
Rhea-AI Summary
PetVivo Holdings, Inc. announces the issuance of a notice of allowance for a patent application by the United States Patent and Trademark Office (USPTO) related to the Company’s proprietary biomaterials and corresponding products. The patent provides protection for a broad range of proprietary products, including the biocompatible sponge-like particles used in PetVivo’s signature product, Spryng™ with OsteoCushion™ Technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
-
Rhea-AI Summary
PetVivo Holdings, a company specializing in innovative medical devices and therapeutics for companion animals, will be participating in The Microcap Conference from January 30 to February 1, 2024. CEO John Lai will be presenting on January 31 & February 1, 2024, with the management team conducting one-on-one meetings throughout the conference. Interested parties can register to attend on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
-
News
Rhea-AI Summary
PetVivo Holdings, an emerging biomedical device company (NASDAQ: PETV & PETVW), will exhibit its lead product, Spryng with OsteoCushion Technology, at the Veterinary Meeting & Expo Conference from January 14th to 17th, 2024. The intra-articular injectable veterinary medical device is designed to manage joint-related afflictions such as osteoarthritis, and the company aims to network with industry leaders at the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.5%
Tags
Rhea-AI Summary
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) has entered into a definitive distribution agreement with Covetrus North America, LLC to market and promote its veterinary medical device, Spryng™ with OsteoCushion™ technology, throughout the United States. Covetrus sales and marketing activities will commence on January 1, 2024. This strategic partnership aims to benefit the veterinary industry, the veterinarians, the animals receiving Spryng, and the owners benefiting from the enhanced medical outcomes of their animals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
-
News
Rhea-AI Summary
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) achieved a significant milestone by distributing over 4500 syringes of Spryng™ with OsteoCushion™ technology to veterinarians in 2023. This represents a 60% increase from the previous year. The positive outcomes experienced by animals injected with Spryng have driven its momentum, with high enthusiasm from veterinarians and upcoming clinical studies and trade show exposure expected to further boost distribution in the new year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
41.46%
Tags
-
Rhea-AI Summary
PetVivo Holdings, Inc. (PETV & PETVW) achieves a significant milestone by selling its signature product Spryng™ with OsteoCushion™ Technology to over 600 veterinary clinics in 49 states.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.02%
Tags
Rhea-AI Summary
PetVivo Holdings, Inc. (PETV, PETVW) will be showcasing its lead product, SPRYNG™ with OsteoCushion™ Technology at the American Association Equine Practitioners conference, aiming to network with industry professionals and drive forward its innovative veterinary medical device. The conference will be held from November 29th to December 2nd, 2023 at the San Diego Convention Center in San Diego, California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.49%
Tags
-
Rhea-AI Summary
PetVivo Holdings, Inc. (Nasdaq: PETV) announces financial results for the three months ended September 30, 2023. Key highlights include the release of clinical study results for Spryng™, raising $2.35 million from stock offerings, and entering into an ATM Sales Agreement with ThinkEquity, LLC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.14%
Tags
-
Rhea-AI Summary
PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW) will report financial results on November 14, 2023, after market close. The company will host a conference call to discuss these results at 4:00 p.m. CT (5:00 p.m. ET) on the same day. Attendees can register and access the webcast on PetVivo’s Investor Relations website. A replay of the webcast will be available through the same link. Participants can also access the call using the provided dial-in details.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.93%
Tags
Rhea-AI Summary
PetVivo Holdings, Inc. announced that two members of its Scientific/Veterinarian Team will present at the AAEP annual convention. Tom Yarbrough will discuss new classes of joint therapeutics, while Joseph Manning will talk about a novel collagen-elastin hydrogel microparticles biomaterial for joint conditions in equines. The presentations will take place from November 30th to December 2nd, 2023 in San Diego, California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.18%
Tags
FAQ
What is the current stock price of PETVIVO HOLDINGS (PETV)?
The current stock price of PETVIVO HOLDINGS (PETV) is $0.57 as of December 24, 2024.
What is the market cap of PETVIVO HOLDINGS (PETV)?
The market cap of PETVIVO HOLDINGS (PETV) is approximately 9.2M.
What is PetVivo Holdings Inc's focus?
PetVivo Holdings Inc focuses on licensing and commercializing innovative medical devices for pets, known as pet therapeutics.
How does PetVivo leverage investments in other industries?
PetVivo leverages investments in the human biomaterials and medical device industries to efficiently bring therapeutics to pets.
What is PetVivo's strategy regarding proprietary products?
PetVivo in-licenses proprietary products from human medical device companies specifically for use in pets.
What are the wholly-owned subsidiaries of PetVivo Holdings Inc?
PetVivo Holdings Inc's wholly-owned subsidiaries include PetVivo, Inc., Gel-Del Technologies, Inc., and CosmetaLife Corporation.
What is the goal of PetVivo Holdings Inc?
The goal of PetVivo Holdings Inc is to commercialize therapeutics for pets in a capital and time-efficient manner.
What industry does PetVivo Holdings Inc operate in?
PetVivo Holdings Inc operates in the biomedical device industry with a focus on pet therapeutics.
How does PetVivo Holdings Inc differentiate itself in the market?
PetVivo Holdings Inc differentiates itself by focusing on innovative medical devices for pets and leveraging investments in related industries.
Where is PetVivo Holdings Inc headquartered?
PetVivo Holdings Inc is headquartered in the United States.
What is the relationship between PetVivo Holdings Inc and Gel-Del Technologies, Inc?
Gel-Del Technologies, Inc is a wholly-owned subsidiary of PetVivo Holdings Inc.
What is the significance of CosmetaLife Corporation to PetVivo Holdings Inc?
CosmetaLife Corporation is a wholly-owned subsidiary of PetVivo Holdings Inc, playing a role in the company's operations.
PETVIVO HOLDINGS INC